HURN (HURN) Stock Analysis
Verdict: BUY
Record earnings beats and a major 2026 guidance raise propel HURN, but aggressive insider selling and a high debt load cap the upside.
Investment score: 74/100
Huron is demonstrating strong operational leverage in its Healthcare and Education segments, evidenced by a 4-quarter streak of earnings beats and a significant guidance upgrade for 2026. Despite a 50% weekly move, the forward valuation remains reasonable compared to high-growth peers like EXPO and INOD.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| KBR | 10.35 | 2.67 | 0.56 | 11.26 | — | 0.05 |
| AMTM | 36.22 | 1.15 | 0.37 | 9.16 | — | 0.01 |
| EXPO | 39.37 | 10.91 | 10.63 | 26.54 | — | 0.28 |
| CBZ | 26.56 | 1.79 | 1.07 | 7.40 | — | 0.04 |
| INOD | 48.84 | 15.28 | 6.92 | 32.50 | — | 0.14 |